Igenomix portfolio includes pioneering genetic tests to help reproductive-health professionals to analyse and treat their patients before, during and after their reproductive journey.
Vitrolife delivers innovative, high-quality products to ensure optimal care at every stage of the IVF journey, from error prevention and gamete handling to embryo evaluation and cryopreservation.
For decades of innovation, we have made a difference
Our passion and commitment to making a difference in reproductive health has never been more dedicated.
Discover our values through the voices of those within the Vitrolife Group.
Latest financial report
Interim report Q3 2024: Improved growth with solid margins
We maintained strong momentum in Consumables, with double-digit growth in both media and disposable devices where we are taking share in most markets across the globe.
Press Releases
Financial Calendar
-
30 Jan 2025
Fourth quarter and full year report 2024
-
27 Mar 2025
Annual and sustainability report 2024
-
24 Apr 2025
Interim report Q1, 2025
Careers
The Vitrolife Group offers an attractive workplace with an opportunity to work for a higher purpose, a purpose that makes a difference in people’s lives worldwide.
Investor relations
Our aim is to have a strong capital base to enable continued high growth, both organically and through acquisitions. We strive to achieve growth through profitability.
Sustainability
Ensuring sustainability in everything we do is one of our key strategic priorities. Learn more on our approach and sustainability themes.